<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sera from patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) were tested for antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus (EBV) determined antigens and for antibodies directed against various EBV-specific antigens </plain></SENT>
<SENT sid="1" pm="."><plain>No correlation was found between EBV serology and ADCC in sera selected for high or low titres against the membrane antigens (MA) or in consecutive sera from three patients with isolated late <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> recurrences </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, no correlation was found between ADCC and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development </plain></SENT>
</text></document>